Dwibedi, Chinmay http://orcid.org/0000-0001-6416-4440
Ekström, Ola
Brandt, Jasmine
Adiels, Martin
Franzén, Stefan
Abrahamsson, Birgitta http://orcid.org/0000-0003-4284-2188
Rosengren, Anders H. http://orcid.org/0000-0002-9333-5736
Article History
Received: 9 May 2023
Accepted: 8 November 2023
First Online: 4 January 2024
Competing interests
: S.F. is an employee at AstraZeneca and reports owning stock in AstraZeneca. Study drugs were provided by AstraZeneca AB, Sweden (dapagliflozin), and Novo Nordisk A/S, Denmark (semaglutide), and Libre Pro glucose sensors were provided by Abbott Diabetes Care, USA, as part of investigator-sponsored study agreements. These companies had no role in the study execution, which was performed by academic investigators. All other authors declare no competing interest.